Physician profile
Otis Warr
NPI 1043214323
$1,821.79
in general payments reported to CMS, 2019-2025
20 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $74.40 · 2021: $152 · 2022: $402 · 2023: $315 · 2024: $182 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.85 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $480.59 | 2019-2025 | |
| Abbott Laboratories | $229.55 | 2019-2025 | Jot Dx, Navitor, Aveir |
| Pfizer INC. | $192.93 | 2019-2025 | |
| Philips North America LLC | $176.09 | 2019-2024 | (792) Multi Modality Ivus Other Systems |
| Shockwave Medical, INC | $146.76 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $130.35 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Amgen INC. | $89.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $65.76 | 2022-2025 | Verquvo |
| Cardiva Medical, INC. | $51.34 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Baxter Healthcare | $42.26 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $39.67 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.13 | 2020-2023 | Camzyos |
| Abiomed | $32.10 | 2023 | Impella |
| Irhythm Technologies, INC. | $24.04 | 2024 | Zio Monitor, Zio Xt Patch |
| Lantheus Medical Imaging, INC. | $16.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.92 | 2023 | Farxiga |
| Esperion Therapeutics, INC. | $14.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.69 | 2019 | |
| Gilead Sciences, INC. | $12.20 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Otis Warr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.